• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

膀胱非肌层浸润性高级别尿路上皮癌。哪些因素会影响根治性膀胱切除术时的分期过低?

Non-muscle invasive high grade urothelial carcinoma of the bladder. Which factors can influence understaging at the time of radical cystectomy?

作者信息

Minardi Daniele, Milanese Giulio, Parri Gianni, Lacetera Vito, Muzzonigro Giovanni

机构信息

Department of Clinic and Specialistic Sciences, Urology, Polytechnic University of the Marche Region, Azienda Ospedaliero-Universitaria Ospedali Riuniti, Ancona.

出版信息

Arch Ital Urol Androl. 2016 Mar 31;88(1):13-6. doi: 10.4081/aiua.2016.1.13.

DOI:10.4081/aiua.2016.1.13
PMID:27072170
Abstract

OBJECTIVE

To evaluate the main factors which influence understaging in patients with T1G3 non-muscle invasive bladder cancer (NMIBC).

MATERIALS AND METHODS

109 patients with T1/G3 underwent transurethral resection of bladder tumor (TURBT) and then radical cystectomy (RC) with pelvic lymph nodes dissection. A number of variables were considered when evaluating the detection of understaging. We considered the patients age and gender, as well as the size, number, location and morphology of their tumor. We also considered coexistence of bladder carcinoma in situ (CIS), microscopic vascular invasion and deep lamina propria invasion. The level of experience of the surgeon was also analyzed.

RESULTS

in RC samples muscle invasion, that is understaging, was detected in 74 (67.9%) patients, while 35 (32.1%) patients were appropriately staged. In these cohort of patients with high grade tumors, understaging was associated with deep lamina propria and microscopic vascular invasion, multiple tumors, tumor size > 6 cm, tumor location (trigone and dome), presence of residual tumor; age, gender, tumor morphology, CIS associated, and experience of urological surgeon were not associated with clinical understaging.

CONCLUSIONS

in our study, evaluating patients with high grade NMIBC at first TURBT, we identified some risk factors that need to be considered and that are able to increase the risk of understaging: deep lamina propria and microscopic vascular invasion, multiple tumors, tumor size > 6 cm, tumor location (trigone and dome), presence of residual tumor. When these risk factors are present, performing an early cystectomy, and not a re-TURBT, could lower the risk of worse pathological finding due to rapid disease progression of the high grade tumors, and can prolong survival.

摘要

目的

评估影响T1G3非肌层浸润性膀胱癌(NMIBC)患者分期过低的主要因素。

材料与方法

109例T1/G3患者接受了经尿道膀胱肿瘤切除术(TURBT),随后进行了根治性膀胱切除术(RC)及盆腔淋巴结清扫术。评估分期过低的检测情况时考虑了多个变量。我们考虑了患者的年龄和性别,以及肿瘤的大小、数量、位置和形态。我们还考虑了原位膀胱癌(CIS)的共存、微小血管侵犯和深层固有层侵犯。同时分析了外科医生的经验水平。

结果

在RC样本中,74例(67.9%)患者检测到肌层浸润,即分期过低,而35例(32.1%)患者分期正确。在这些高级别肿瘤患者队列中,分期过低与深层固有层和微小血管侵犯、多发肿瘤、肿瘤大小>6 cm、肿瘤位置(三角区和穹窿部)、残留肿瘤的存在有关;年龄、性别、肿瘤形态、CIS相关性以及泌尿外科医生的经验与临床分期过低无关。

结论

在我们的研究中,对首次接受TURBT的高级别NMIBC患者进行评估时,我们确定了一些需要考虑的风险因素,这些因素会增加分期过低的风险:深层固有层和微小血管侵犯、多发肿瘤、肿瘤大小>6 cm、肿瘤位置(三角区和穹窿部)、残留肿瘤的存在。当存在这些风险因素时,早期进行膀胱切除术而非再次TURBT,可降低因高级别肿瘤疾病快速进展导致更差病理结果的风险,并可延长生存期。

相似文献

1
Non-muscle invasive high grade urothelial carcinoma of the bladder. Which factors can influence understaging at the time of radical cystectomy?膀胱非肌层浸润性高级别尿路上皮癌。哪些因素会影响根治性膀胱切除术时的分期过低?
Arch Ital Urol Androl. 2016 Mar 31;88(1):13-6. doi: 10.4081/aiua.2016.1.13.
2
Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection.在经尿道膀胱肿瘤切除术再分期时,对于残余 T1 膀胱癌患者,即刻根治性膀胱切除术的作用。
BJU Int. 2013 Jul;112(1):54-9. doi: 10.1111/j.1464-410X.2012.11391.x. Epub 2012 Nov 13.
3
Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.再次经尿道膀胱肿瘤切除术(re-cTURBT)作为pT1期高级别(HG)疾病复发和进展的风险指标是否有用?一项单中心经验。
Arch Ital Urol Androl. 2017 Dec 31;89(4):272-276. doi: 10.4081/aiua.2017.4.272.
4
The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.复发性高危浅表性膀胱肿瘤患者根治性膀胱切除术的最佳时机。
BJU Int. 2004 Dec;94(9):1258-62. doi: 10.1111/j.1464-410X.2004.05228.x.
5
Timing and outcomes for radical cystectomy in nonmuscle invasive bladder cancer.非肌层浸润性膀胱癌根治性膀胱切除术的时机和结果。
Curr Opin Urol. 2013 Sep;23(5):423-8. doi: 10.1097/MOU.0b013e328363e46f.
6
Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.高危浅表性膀胱肿瘤患者膀胱内卡介苗治疗失败后的膀胱切除术:术前前列腺受累作为一个预后因素。
Eur Urol. 2005 Jul;48(1):53-9; discussion 59. doi: 10.1016/j.eururo.2005.03.021. Epub 2005 Apr 7.
7
Clinical significance of urothelial carcinoma ambiguous for muscularis propria invasion on initial transurethral resection of bladder tumor.初发经尿道膀胱肿瘤切除术时肌层浸润状态不明确的尿路上皮癌的临床意义。
World J Urol. 2020 Feb;38(2):389-395. doi: 10.1007/s00345-019-02782-y. Epub 2019 Apr 27.
8
The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer.膀胱尿路上皮癌患者经尿道膀胱肿瘤切除术及膀胱切除术标本中淋巴管侵犯对患者生存的意义。
BJU Int. 2009 Feb;103(4):475-9. doi: 10.1111/j.1464-410X.2008.08011.x. Epub 2008 Oct 6.
9
[Radical cystectomy in patients with non-muscle invasive bladder cancer who fail BCG therapy].卡介苗治疗失败的非肌层浸润性膀胱癌患者的根治性膀胱切除术
Actas Urol Esp. 2010 Jan;34(1):63-70.
10
Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy.临床 T1 期尿路上皮癌患者行根治性膀胱切除术的分期不足发生率及预测因素。
BJU Int. 2014 Jun;113(6):894-9. doi: 10.1111/bju.12245. Epub 2014 Apr 3.

引用本文的文献

1
Metastasis development in non-muscle-invasive bladder cancer.非肌层浸润性膀胱癌中的转移发展
Nat Rev Urol. 2024 Nov 20. doi: 10.1038/s41585-024-00963-y.
2
Intravesical Contrast-Enhanced MRI: A Potential Tool for Bladder Cancer Surveillance and Staging.膀胱内对比增强 MRI:膀胱癌监测和分期的潜在工具。
Curr Oncol. 2023 Apr 30;30(5):4632-4647. doi: 10.3390/curroncol30050350.
3
Treatment Outcomes of High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) in Real-World Evidence (RWE) Studies: Systematic Literature Review (SLR).
真实世界证据(RWE)研究中高危非肌肉浸润性膀胱癌(HR-NMIBC)的治疗结果:系统文献综述(SLR)
Clinicoecon Outcomes Res. 2022 Jan 10;14:35-48. doi: 10.2147/CEOR.S341896. eCollection 2022.
4
Repeat transurethral resection is still an essential tool in treating non-muscle invasive bladder cancer: the Western Australian experience.经尿道重复切除术仍是治疗非肌层浸润性膀胱癌的重要手段:西澳大利亚的经验
Bladder (San Franc). 2020 Apr 2;7(2):e42. doi: 10.14440/bladder.2020.814. eCollection 2020.
5
Clinical significance of urothelial carcinoma ambiguous for muscularis propria invasion on initial transurethral resection of bladder tumor.初发经尿道膀胱肿瘤切除术时肌层浸润状态不明确的尿路上皮癌的临床意义。
World J Urol. 2020 Feb;38(2):389-395. doi: 10.1007/s00345-019-02782-y. Epub 2019 Apr 27.
6
Calgranulin A (S100A8) Immunostaining: A Future Candidate for Risk Assessment in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC).钙粒蛋白 A(S100A8)免疫染色:非肌肉浸润性膀胱癌(NMIBC)患者风险评估的未来候选标志物。
Adv Ther. 2018 Nov;35(11):2054-2068. doi: 10.1007/s12325-018-0789-7. Epub 2018 Sep 19.
7
SIU-ICUD on bladder cancer: pathology.国际泌尿病理学会(SIU-ICUD)关于膀胱癌的病理学。
World J Urol. 2019 Jan;37(1):41-50. doi: 10.1007/s00345-018-2466-5. Epub 2018 Sep 14.